Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Seagen Inc (NQ: SGEN )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 13, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Seagen Inc

< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2021
Upgrades JP Morgan upgraded the previous rating for New Relic Inc (NYSE: 
Via Benzinga
Seagen to Highlight Two Novel Antibody-Drug Conjugates (ADCs) at the SITC 36th Annual Meeting
From Seagen Inc.
Via Business Wire
Expert Ratings For Seagen
Seagen (NASDAQ:SGEN) has observed the following analyst ratings within the... 
Via Benzinga
Earnings Scheduled For October 28, 2021
Companies Reporting Before The Bell • LendingTree (NASDAQ:TREE) is estimated to report quarterly earnings at $0.57 per share on revenue of $292.63 million. •... 
Via Benzinga
Notable Seagen Insider Trades $7.4M In Company Stock
Jean I Liu, Gc/EVP And Leg Afairs at Seagen (NASDAQ:SGEN), made a large buy and sell of company shares on November 1, according to a new SEC filing. What Happened: A Form 4 filing... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
Seagen to Highlight Multiple ADCETRIS® (brentuximab vedotin) Data Presentations at the Upcoming 2021 American Society of Hematology (ASH) Annual Meeting
From Seagen Inc.
Via Business Wire
CNBC's Final Trades: Seagen, Dollar Tree And This Pharma Major
On CNBC’s “Halftime Report Final Trades,&rd... 
Via Benzinga
Notable Seagen Insider Trades $7.4M In Company Stock
Todd E Simpson, Chief Financial Officer at Seagen (NASDAQ:SGEN), made a large buy and sell of company shares on October 29, according to a new SEC filing. What Happened: A Form 4... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Gilead, Merck to Study Trodelvy-Keytruda Combo For Breast Cancer Gilead, Inc... 
Via Benzinga
Seattle Genetics (SGEN) Q3 2021 Earnings Call Transcript
SGEN earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Seagen Reports Third Quarter 2021 Financial Results
From Seagen Inc.
Via Business Wire
Seattle Genetics's Earnings Outlook
Seattle Genetics (NASDAQ:SGEN) is set to give its latest quarterly earnings report on Thursday, 2021-10-28. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
10 Biggest Price Target Changes For Wednesday
Raymond James raised Alphabet Inc. (NASDAQ:GOOGL 
Via Benzinga
2 Stocks That Have Doubled the S&P 500's Returns Over the Past 5 Years and Could Still Go Higher
These companies just keep on growing. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Health Care Sector Appears to Be a Drag on Positive UnitedHealth Earnings
Stock futures were pointing to a higher open even before Goldman Sachs (NYSE: GS) reported better than expected earnings. Goldman rose 2.25% before the open helping to... 
Via Benzinga
Seagen and Astellas Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV® (enfortumab vedotin-ejfv) With Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer
From Seagen Inc.
Via Business Wire
Seagen to Host Conference Call and Webcast Discussion of Third Quarter 2021 Financial Results on October 28, 2021
From Seagen Inc.
Via Business Wire
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new... 
Via Benzinga
A Bullish Sign Appears On Seagen's Chart
If history is any guide, there may be good fortune ahead for shares of Seagen(NASDAQ:SGEN). A so-called "golden cross" has formed on its chart and, not surprisingly,... 
Via Benzinga
Seagen Announces Last Patient Enrolled in Phase 2 MOUNTAINEER Trial Evaluating TUKYSA® (Tucatinib) Regimen in HER2-Positive Metastatic Colorectal Cancer
From Seagen Inc.
Via Business Wire
Japan’s MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer
From Seagen Inc.
Via Business Wire
Why Genmab's Stock Is Trading Higher Today
Genmab A/S (NASDAQ:GMAB) shares are trading higher after the company, along with Seagen Inc. (NASDAQ: SGEN), announced the FDA has granted accelerated approval to... 
Via Benzinga
Exposures Product Safety
Why Seagen's Stock Is Trading Higher Today
Seagen (NASDAQ:SGEN) shares are trading higher after the company, along with Genmab A/S (NASDAQ: GMAB), announced the FDA has granted accelerated approval to TIVDAKTM... 
Via Benzinga
Exposures Product Safety
FDA Gives Accelerated Approval to Seagen - Genmab's ADC In Cervical Cancer
The FDA handed an accelerated approval to Seagen Inc (NASDAQ: SGEN) and Genmab A/S’ (NASDAQ: GMAB) Tivdak (tisotumab vedotin-tftv, or TV). The... 
Via Benzinga
Exposures Product Safety
Seagen to Host Conference Call and Webcast Discussion on September 21, 2021 to Discuss TIVDAK™ (tisotumab vedotin-tftv) Approval
From Seagen Inc.
Via Business Wire
The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Cerevel Therapeutics... 
Via Benzinga
Exposures COVID-19
Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer
From Genmab A/S
Via Business Wire
Seagen and Genmab Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer
From Seagen Inc.
Via Business Wire
Seagen, Genmab Present Tisotumab Vedotin Combo Data In Cervical Cancer
Seagen Inc (NASDAQ: SGEN) and Genmab A/S (NASDAQ: GMAB) have interim data from two Phase 1b/2 innovaTV 205 trial cohorts. The trial is evaluating its... 
Via Benzinga
Seagen and Genmab Present Interim Results From the innovaTV 205 Study for Tisotumab Vedotin Combination Therapy Treatment of Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2021
From Seagen Inc.
Via Business Wire
< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.